Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Cocaine-Levamisole Thrombovasculopathy: A Report From the Southern Network On Adverse Reactions (SONAR) Project

Charles Bennett, MD, PhD, MPP, Irene Dy, Peter Wiernik, MD, Jennie Buchanan, Richard Dart, Brian Edlin, Erin Gilbert, Priya Mahindra, Alanna Murday, BS, Zaina Parvez Qureshi, PhD, MPH

Blood (2012) 120 (21): 3403.

https://doi.org/10.1182/blood.V120.21.3403.3403

Published: 2012

Journal Articles

Association of Renal Cell Carcinoma and B-Cell Hematological Malignancy

Rangaswamy Chintapatla, MD, Leticia Varella, M.D, Peter Wiernik, MD, Valerie Rusciano, R.N, Janice P. Dutcher, MD

Blood (2012) 120 (21): 5086.

https://doi.org/10.1182/blood.V120.21.5086.5086

Published: 2012

Journal Articles

Outcome in Philadelphia Chromosome Positive (Ph+) Adult ALL Patients (Pts) May Be More Determined by CD25 Expression Than by Ph Status Per Se.

Elisabeth Paietta, Xiaochun Li, Ph.D., Sue Richards, Janis Racevskis, Ph.D., Gordon W. Dewald, PhD, PhD, FACMG, Jacob M. Rowe, MD, Martin S Tallman, Hillard M Lazarus, MD, Mark R. Litzow, MD, Anthony H. Goldstone, FRCP, FRCPath, Peter Wiernik, MD

Blood (2008) 112 (11): 1500.

https://doi.org/10.1182/blood.V112.11.1500.1500

Published: 2008

Journal Articles

Active Immunotherapy with Mitumprotimut-T (FavId®, Id-KLH) Following Rituximab Induction in Patients (pts) with Follicular B-Cell Lymphoma (FL): Progression Free Survival (PFS) at 4-Year Follow Up.

Omer Koc, MD, Charles Redfern, MD, Peter Wiernik, MD, Fred Rosenfelt, MD, Jane Winter, MD, Troy Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, John Hainsworth, MD, Thomas S. Lin, MD, PhD, Rene Castillo, MD, Nalini Janakiraman, MD, John Bender, PharmD

Blood (2007) 110 (11): 2567.

https://doi.org/10.1182/blood.V110.11.2567.2567

Published: 2007

Journal Articles

Extended Follow-Up and Analysis with Central Radiological Review of Patients Receiving FavId ® (Id/KLH) Vaccine Following Rituximab.

Omer Koc, MD, Charles Redfern, MD, Peter Wiernik, MD, Fred Rosenfelt, MD, Jane Winter, MD, Troy Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas Lin, MD, PhD, Rene Castillo, MD, Nalini Janakiraman, MD, Dan Gold, PhD, John Gutheil, MD, John Bender, PharmD

Blood (2005) 106 (11): 772.

https://doi.org/10.1182/blood.V106.11.772.772

Published: 2005

Journal Articles

Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).

John Gregory, MD, Haesook Kim, PhD, Todd Alonzo, MD, Rob Gerbing, PhD, Angela Ogden, MD, William Woods, MD, Howard Weinstein, MD, Lois Shepherd, MD, Charles Schiffer, MD, Frederick Appelbaum, MD, Cheryl Willman, MD, Peter Wiernik, MD, Jacob Rowe, MD, Martin Tallman, MD, James Feusner, MD

Blood (2005) 106 (11): 894.

https://doi.org/10.1182/blood.V106.11.894.894

Published: 2005

NARROW

Cocaine-Levamisole Thrombovasculopathy: A Report From the Southern Network On Adverse Reactions (SONAR) Project

Association of Renal Cell Carcinoma and B-Cell Hematological Malignancy

Outcome in Philadelphia Chromosome Positive (Ph+) Adult ALL Patients (Pts) May Be More Determined by CD25 Expression Than by Ph Status Per Se.

Active Immunotherapy with Mitumprotimut-T (FavId®, Id-KLH) Following Rituximab Induction in Patients (pts) with Follicular B-Cell Lymphoma (FL): Progression Free Survival (PFS) at 4-Year Follow Up.

Extended Follow-Up and Analysis with Central Radiological Review of Patients Receiving FavId ® (Id/KLH) Vaccine Following Rituximab.

Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Email alerts

ASH Publications

American Society of Hematology

Cocaine-Levamisole Thrombovasculopathy: A Report From the Southern Network On Adverse Reactions (SONAR) Project

Association of Renal Cell Carcinoma and B-Cell Hematological Malignancy

Outcome in Philadelphia Chromosome Positive (Ph+) Adult ALL Patients (Pts) May Be More Determined by CD25 Expression Than by Ph Status Per Se.

Active Immunotherapy with Mitumprotimut-T (FavId®, Id-KLH) Following Rituximab Induction in Patients (pts) with Follicular B-Cell Lymphoma (FL): Progression Free Survival (PFS) at 4-Year Follow Up.

Extended Follow-Up and Analysis with Central Radiological Review of Patients Receiving FavId ® (Id/KLH) Vaccine Following Rituximab.

Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only